---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001897"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:55:01.258902+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium Q4 record net revenue $129.6M; FY22 adj. EBITDA $266.0M, reaffirms 2023 guidance

## Summary
- Q4 product revenue $129.6M (up from $27.4M YoY); GAAP net loss $(7.2)M vs $(25.0)M YoY.
- FY22 product revenue $463.9M (up 68% YoY); non-GAAP adjusted EPS $3.96 vs $2.58.
- Completed BDSI integration with $85M run-rate synergies; resolved all 27 opioid lawsuits.
- Board authorized $100M share repurchase program in Jan 2023; cash balance $173.7M at year-end.
- Reaffirms 2023 guidance: product revenue $565-580M, adjusted EBITDA $355-370M.

## SEC filing metadata
- accession: 0001558370-23-001897
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/coll-20230223x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001897
- JSON: https://secwatch.observer/filing/0001558370-23-001897.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001897.txt

## Key facts
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended December 31, 2022 results: revenue $129.6 million, net income $(7.2) million, EPS $(0.21) GAAP loss per share (basic and diluted). Guidance reaffirmed.
  - Period: the quarter ended December 31, 2022
  - Revenue: $129.6 million
  - Net income: $(7.2) million
  - EPS: $(0.21) GAAP loss per share (basic and diluted)
  - Guidance: reaffirmed
  - Result: reported results
  source text: ● Product revenues, net were $129.6 million for the quarter ended December 31, 2022 (the “2022 Quarter”), compared to $27.4 million for the quarter ended December 31, 2021 (the “2021 Quarter”). ● GAAP operating expenses were $38.0 million for the 2022 Quarter, compared to $32.8 million for the 2021 Quarter. Adjusted operating expenses, which exclude stock-based compensation expense of $5.7 million and acquisition related expenses of $0.1 million, were $32.3 million for the 2022 Quarter, compared to $20.4 million for the 2021 Quarter, which excluded stock-based compensation expense of $4.9 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million. ● GAAP net loss for the 2022 Quarter was $(7.2) million, with $(0.21) GAAP loss per share (basic and diluted), compared to GAAP net loss for the 2021 Quarter of $(25.0) million, with $(0.73) GAAP loss per share (basic and diluted).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported the year ended December 31, 2022 results: revenue $463.9 million, net income $(25.0) million, EPS $(0.74) GAAP loss per share (basic and diluted). Guidance reaffirmed.
  - Period: the year ended December 31, 2022
  - Revenue: $463.9 million
  - Net income: $(25.0) million
  - EPS: $(0.74) GAAP loss per share (basic and diluted)
  - Guidance: reaffirmed
  - Result: reported results
  source text: ● Product revenues, net were $463.9 million for the year ended December 31, 2022 (“FY 2022”), compared to $276.9 million for the year ended December 31, 2021 (“FY 2021”). ● GAAP operating expenses were $176.2 million for FY 2022, compared to $133.0 million for FY 2021. Adjusted operating expenses, which exclude stock-based compensation of $22.9 million and acquisition related expenses of $31.3 million, were $122.0 million for FY 2022, compared to $101.2 million for FY 2021, which excluded stock-based compensation expense of $24.3 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million. ● GAAP net loss for FY 2022 was $(25.0) million, with $(0.74) GAAP loss per share (basic and diluted), compared to GAAP net income for FY 2021 of $71.5 million, with $2.05 GAAP earnings per share (basic) and $1.86 GAAP earnings per share (diluted).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.